Medicure Inc. (TSXV: MPH)
Health Care · Biotechnology · CA
CA$1.37
+7.03% today · +21.9% 1Y
Medicure Inc. (TSXV: MPH) operates in the Biotechnology industry within the Health Care sector. The company is valued at $9.70M and employs 25 people.
Over the last twelve months the share price has gained 21.9%, trading between 0.85 and 1.43.
Tweenvest scores Medicure Inc. across four factors: quality 66/100, value 51/100, growth 50/100. Its strongest factor is quality.
MPH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.70M
- Revenue (TTM)
- $22.59M
- P/E
- —
- EPS
- -0.72
- Dividend yield
- —
- Beta (5Y)
- 1.04
- 52-week high
- CA$1.43
- 52-week low
- CA$0.85
- Avg volume (3M)
- —
- Shares outstanding
- 10.44M
- Employees
- 25
- Next earnings
- —
About Medicure Inc.
Medicure Inc. is a biopharmaceutical firm focused on developing, researching, and commercializing therapeutic solutions for cardiovascular conditions across Canada and the United States. Its product portfolio includes AGGRASTAT, an injectable glycoprotein GP IIb/IIIa receptor antagonist prescribed for acute coronary syndromes, such as unstable angina and non-Q-wave myocardial infarction. The company also provides ZYPITAMAG, a medication used to manage primary hyperlipidemia and mixed dyslipidemia. Additionally, Medicure offers the ReDS system, a non-invasive medical device designed to measure lung fluid levels, aiding in the management of congestive heart failure. Another key offering is Sodium Nitroprusside injection, utilized for rapidly lowering blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension for surgical bleeding reduction, and treating acute congestive heart failure. These products are made available through both retail pharmacy networks and online platforms. Established in 1997, Medicure Inc. is headquartered in Winnipeg, Canada.
- ISIN
- CA58469E4085
- Founded
- 1997
- Listed since
- Sep 6, 2012
- Exchange
- TSX Venture Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.03 | -1.79% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.19 | -0.24% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.67 | -0.07% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.12 | -0.67% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $820.43 | -1.58% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $145.92 | -8.13% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.